John M. Maraganore M.D., Ph.D.
Net Worth

Last updated:

What is John M. Maraganore M.D., Ph.D. net worth?

The estimated net worth of Dr. John M. Maraganore M.D., Ph.D. is at least $280,904,700 as of 10 Dec 2021. He owns shares worth $107,060,327 as insider, has earned $130,374,373 from insider trading and has received compensation worth at least $43,470,000 in Alnylam Pharmaceuticals, Inc..

What is the salary of John M. Maraganore M.D., Ph.D.?

Dr. John M. Maraganore M.D., Ph.D. salary is $2,070,000 per year as Chief Executive Officer & Executive Director in Alnylam Pharmaceuticals, Inc..

How old is John M. Maraganore M.D., Ph.D.?

Dr. John M. Maraganore M.D., Ph.D. is 62 years old, born in 1963.

What stocks does John M. Maraganore M.D., Ph.D. currently own?

As insider, Dr. John M. Maraganore M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Alnylam Pharmaceuticals, Inc. (ALNY) Chief Executive Officer & Executive Director 238,378 $449.12 $107,060,327

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ALNY logo
ALNY
Alnylam Pharmaceuticals, Inc.
$449.12

John M. Maraganore M.D., Ph.D. insider trading

Alnylam Pharmaceuticals, Inc.

Dr. John M. Maraganore M.D., Ph.D. has made 47 insider trades between 2004-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 98,636 units of ALNY stock on 21 Nov 2018. As of 10 Dec 2021 he still owns at least 238,378 units of ALNY stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 5,367 $86.69 $465,254
Option
Stock Option (right to buy) 5,367 $86.69 $465,254
Option
Stock Option (right to buy) 33,978 $7.1 $241,244
Sale
Common Stock 33,978 $172.3 $5,854,545
Option
Common Stock 33,978 $7.1 $241,244
Sale
Common Stock 33,979 $199.85 $6,790,771
Option
Common Stock 33,979 $7.1 $241,251
Option
Stock Option (right to buy) 33,979 $7.1 $241,251
Option
Common Stock 33,979 N/A N/A
Sale
Common Stock 33,979 N/A N/A
Option
Stock Option (right to buy) 33,979 N/A N/A
Sale
Common Stock 33,979 N/A N/A
Sale
Common Stock 33,979 $149.18 $5,069,089
Sale
Common Stock 33,979 $149.18 $5,069,089
Sale
Common Stock 33,979 $67.95 $2,309,009
Sale
Common Stock 33,979 $149.18 $5,069,089
Option
Common Stock 33,979 N/A N/A
Sale
Common Stock 33,979 N/A N/A
Option
Stock Option (right to buy) 33,979 $7.1 $241,251
Option
Common Stock 34,765 $9.14 $317,752
Sale
Common Stock 34,765 $125 $4,345,729
Option
Stock Option (right to buy) 34,765 $9.14 $317,752
Option
Stock Option (right to buy) 34,765 $9.14 $317,752
Sale
Common Stock 34,765 $136.01 $4,728,283
Option
Common Stock 34,765 $9.14 $317,752
Option
Stock Option (right to buy) 34,765 $9.14 $317,752
Sale
Common Stock 34,765 $143.43 $4,986,448
Option
Common Stock 34,765 $9.14 $317,752
Sale
Common Stock 34,765 $131.14 $4,559,186
Option
Common Stock 34,765 $9.14 $317,752
Option
Stock Option (right to buy) 34,765 $9.14 $317,752
Option
Stock Option (right to buy) 49,456 $16.43 $812,562
Sale
Common Stock 49,456 $79.68 $3,940,506
Option
Common Stock 49,456 $16.43 $812,562
Option
Common Stock 49,457 $16.43 $812,579
Sale
Common Stock 49,457 $16.43 $812,579
Option
Stock Option (right to buy) 49,457 $16.43 $812,579
Option
Common Stock 98,636 $21.35 $2,105,879
Option
Stock Option (right to buy) 98,636 $21.35 $2,105,879
Sale
Common Stock 50,000 $104.62 $5,231,100
Option
Stock Option (right to buy) 50,000 $21.35 $1,067,500
Option
Common Stock 50,000 $21.35 $1,067,500
Option
Common Stock 1,587 $63 $99,981
Option
Stock Option (right to buy) 1,587 $63 $99,981
Option
Common Stock 73,415 $31.39 $2,304,497
Option
Stock Option (Right to Buy) 73,415 $31.39 $2,304,497
Sale
Common Stock 73,415 $131.35 $9,643,060
Option
Stock Option (Right to Buy) 74,000 $31.39 $2,322,860
Sale
Common Stock 74,000 $127.99 $9,471,482
Option
Common Stock 74,000 $31.39 $2,322,860
Option
Common Stock 1,340 $18.66 $25,004
Option
Stock Option (Right to Buy) 1,340 $18.66 $25,004
Option
Common Stock 30,151 $22.75 $685,935
Option
Stock Option (right to buy) 30,151 $22.75 $685,935
Option
Common Stock 7,540 $12.88 $97,115
Option
Stock Option (Right to Buy) 7,540 $12.88 $97,115
Sale
Common Stock 15,075 $65.28 $984,141
Option
Common Stock 15,075 $22.75 $342,956
Option
Stock Option (right to buy) 15,075 $22.75 $342,956
Sale
Common Stock 15,076 $64.14 $967,005
Option
Stock Option (right to buy) 15,076 $22.75 $342,979
Option
Common Stock 15,076 $22.75 $342,979
Sale
Common Stock 15,075 $67.81 $1,022,236
Option
Common Stock 15,075 $22.75 $342,956
Option
Stock Option (right to buy) 15,075 $22.75 $342,956
Option
Common Stock 15,076 $22.75 $342,979
Option
Stock Option (right to buy) 15,076 $22.75 $342,979
Sale
Common Stock 15,076 $67.91 $1,023,796
Option
Stock Option (Right to Buy) 15,076 $22.75 $342,979
Option
Common Stock 15,076 $22.75 $342,979
Sale
Common Stock 15,076 $70.5 $1,062,903
Option
Stock Option (Right to Buy) 15,076 $22.75 $342,979
Option
Common Stock 15,076 $22.75 $342,979
Sale
Common Stock 15,076 $74.62 $1,125,016
Option
Stock Option (Right to Buy) 58,689 $13.12 $770,000
Option
Common Stock 58,689 $13.12 $770,000
Sale
Common Stock 58,689 $104.99 $6,161,523
Option
Common Stock 69,254 $10.11 $700,158
Sale
Common Stock 58,690 $103.15 $6,053,580
Option
Stock Option (Right to Buy) 69,254 $10.11 $700,158
Purchase
Common Stock 10,000 $95 $950,000
Option
Common Stock 8,205 $9.14 $74,994
Option
Stock Option (Right to Buy) 8,205 $9.14 $74,994
Option
Common Stock 56,834 $7.47 $424,550
Option
Stock Option (Right to Buy) 56,834 $7.47 $424,550
Sale
Common Stock 56,834 $78.67 $4,471,301
Option
Common Stock 56,834 $7.47 $424,550
Sale
Common Stock 56,834 $76.55 $4,350,529
Option
Stock Option (Right to Buy) 56,834 $7.47 $424,550
Sale
Common Stock 56,834 $65.59 $3,727,628
Option
Stock Option (Right to Buy) 56,834 $7.47 $424,550
Option
Common Stock 56,834 $7.47 $424,550
Sale
Common Stock 56,834 $66.08 $3,755,307
Option
Common Stock 56,834 $7.47 $424,550
Option
Stock Option (Right to Buy) 56,834 $7.47 $424,550
Option
Common Stock 56,834 $7.13 $404,942
Sale
Common Stock 56,834 $56.39 $3,204,756
Option
Stock Option (Right to Buy) 56,834 $7.13 $404,942
Option
Common Stock 56,834 $6.78 $385,335
Sale
Common Stock 56,834 $57.42 $3,263,636
Option
Stock Option (Right to Buy) 56,834 $6.78 $385,335
Option
Stock Option (right to buy) 28,707 $19.03 $546,294
Option
Common Stock 28,707 $19.03 $546,294
Option
Common Stock 46,331 $6.78 $314,124
Option
Stock Option (right to buy) 46,331 $6.78 $314,124
Option
Common Stock 12,665 $6.78 $85,869
Option
Stock Option (Right to Buy) 12,665 $6.78 $85,869
Sale
Common Stock 58,947 $56.26 $3,316,122
Option
Stock Option (Right to Buy) 13,684 $0.95 $13,000
Option
Common Stock 58,947 $0.95 $56,000
Sale
Common Stock 60,000 $48.92 $2,935,140
Option
Common Stock 60,000 $0.95 $57,000
Option
Stock Option (Right to Buy) 60,000 $0.95 $57,000
Sale
Common Stock 60,000 $0.95 $57,000
Option
Stock Option (Right to Buy) 60,000 $0.95 $57,000
Option
Common Stock 60,000 $0.95 $57,000
Sale
Common Stock 28,503 $23.5 $669,906
Sale
Common Stock 30,000 $23.47 $704,010
Option
Stock Option (right to buy) 14,102 $0.48 $6,698
Option
Common Stock 18,617 $0.48 $8,843
Purchase
Common Stock 5,581 $10.75 $59,996
Purchase
Common Stock 1,134 $8.81 $9,995
Purchase
Common Stock 1,397 $7.16 $9,996
Purchase
Common Stock 1,411 $7.09 $9,997
Purchase
Common Stock 1,480 $6.75 $9,989
Option
Stock Option (Right to buy) 50,000 $0.48 $23,750
Option
Common Stock 50,000 $0.48 $23,750
Sale
Common Stock 11,800 $21.37 $252,119
Option
Incentive Stock Option 28,200 $21.37 $602,521
Option
Non Qualified Stock Option 11,800 $21.37 $252,119
Option
Common Stock 40,000 $21.37 $854,640
Option
Common Stock 40,000 $21.4 $855,840
Option
Non Qualified Stock Option 40,000 $21.4 $855,840
Sale
Common Stock 40,000 $21.4 $855,840
Sale
Common Stock 39,600 $0.48 $18,810
Option
Common Stock 40,000 $11.32 $452,640
Option
Non Qualified Stock Option 40,000 $11.32 $452,640
Option
Common Stock 750 $0.48 $356
Option
Incentive Stock Option (right to buy) 750 $0.48 $356
Option
Incentive Stock Option (right to buy) 37,500 $0.48 $17,813
Sale
Common Stock 37,500 $0.48 $17,813
Option
Common Stock 37,500 $0.48 $17,813
Option
Incentive Stock Option (right to buy) 37,500 $0.48 $17,813
Option
Common Stock 37,500 $0.48 $17,813
Sale
Common Stock 37,500 $0.48 $17,813
Option
Common Stock 3,000 $0.48 $1,425
Option
Incentive Stock Option (right to buy) 3,000 $0.48 $1,425
Sale
Common Stock 37,500 $15.77 $591,188
Option
Incentive Stock Option (right to buy) 37,500 $0.48 $17,813
Option
Common Stock 37,500 $0.48 $17,813
Option
Common Stock 37,500 $0.48 $17,813
Sale
Common Stock 37,500 $16.05 $601,912
Option
Incentive Stock Option (right to buy) 37,500 $0.48 $17,813
Sale
Common Stock 1,000 $15.05 $15,050
Option
Stock option (right to buy) 37,500 $0.48 $17,813
Sale
Common Stock 41,635 $15.08 $627,939
Option
Common Stock 37,500 $0.48 $17,813
Sale
Common Stock 41,635 $15.38 $640,388
Option
Common Stock 37,500 $0.48 $17,813
Option
Stock option (right to buy) 37,500 $0.48 $17,813
Purchase
Common Stock 1,230 $6 $7,380
Purchase
Common Stock 6,840 $4.82 $32,969
Purchase
Common Stock 100 $4.43 $443

Alnylam Pharmaceuticals key executives

Alnylam Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Akshay K. Vaishnaw (62) Pres of R&D
  • Dr. John M. Maraganore M.D., Ph.D. (62) Chief Executive Officer & Executive Director
  • Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB (62) Pres, Chief Operating Officer & Director
  • Mr. Jeffrey V. Poulton M.B.A. (57) Chief Financial Officer & Executive Vice President
  • Mr. Michael W. Bonney B.A. (67) Executive Chairman